UBS Group’s PLx Pharma Inc. Common Stock PLXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-51,213
| Closed | -$6.66K | – | 10392 |
|
|
2023
Q1 | $6.66K | Sell |
51,213
-32,510
| -39% | -$6.61K | ﹤0.01% | 7902 |
|
|
2022
Q4 | $13.4K | Buy |
83,723
+27,752
| +50% | +$11.6K | ﹤0.01% | 8170 |
|
|
2022
Q3 | $36K | Buy |
55,971
+4,839
| +9% | +$7.13K | ﹤0.01% | 6676 |
|
|
2022
Q2 | $124K | Hold |
51,132
| – | – | ﹤0.01% | 5262 |
|
|
2022
Q1 | $207K | Sell |
51,132
-7,291
| -12% | -$40K | ﹤0.01% | 5325 |
|
|
2021
Q4 | $468K | Buy |
58,423
+18,425
| +46% | +$216K | ﹤0.01% | 5034 |
|
|
2021
Q3 | $772K | Buy |
39,998
+22,986
| +135% | +$402K | ﹤0.01% | 4399 |
|
|
2021
Q2 | $235K | Buy |
17,012
+3,161
| +23% | +$37.4K | ﹤0.01% | 5237 |
|
|
2021
Q1 | $125K | Buy |
13,851
+11,531
| +497% | +$84.3K | ﹤0.01% | 5791 |
|
|
2020
Q4 | $13K | Sell |
2,320
-1,473
| -39% | -$6.52K | ﹤0.01% | 7306 |
|
|
2020
Q3 | $12K | Buy |
3,793
+2,740
| +260% | +$9.18K | ﹤0.01% | 6724 |
|
|
2020
Q2 | $3K | Sell |
1,053
-781
| -43% | -$2.36K | ﹤0.01% | 7576 |
|
|
2020
Q1 | $4K | Buy |
1,834
+781
| +74% | +$3.58K | ﹤0.01% | 7433 |
|
|
2019
Q4 | $5K | Hold |
1,053
| – | – | ﹤0.01% | 7611 |
|
|
2019
Q3 | $5K | Sell |
1,053
-2,491
| -70% | -$14.5K | ﹤0.01% | 7507 |
|
|
2019
Q2 | $26K | Buy |
3,544
+627
| +21% | +$3.4K | ﹤0.01% | 6449 |
|
|
2019
Q1 | $16K | Sell |
2,917
-9,595
| -77% | -$46.9K | ﹤0.01% | 6515 |
|
|
2018
Q4 | $19K | Sell |
12,512
-769
| -6% | -$2.74K | ﹤0.01% | 6847 |
|
|
2018
Q3 | $54K | Buy |
13,281
+1,441
| +12% | +$5.42K | ﹤0.01% | 6108 |
|
|
2018
Q2 | $46K | Sell |
11,840
-2,157
| -15% | -$8.81K | ﹤0.01% | 6044 |
|
|
2018
Q1 | $47K | Buy |
13,997
+1,086
| +8% | +$6.88K | ﹤0.01% | 5762 |
|
|
2017
Q4 | $89K | Buy |
12,911
+1,071
| +9% | +$7.43K | ﹤0.01% | 5445 |
|
|
2017
Q3 | $76K | Buy |
11,840
+11,787
| +22,240% | +$75.6K | ﹤0.01% | 5510 |
|
|
2017
Q2 | $0 | Sell |
53
-1
| -2% | -$7 | ﹤0.01% | 8094 |
|
|
2017
Q1 | $1K | Sell |
54
-9
| -14% | -$98 | ﹤0.01% | 7491 |
|
|
2016
Q4 | $1K | Sell |
63
-14
| -18% | -$514 | ﹤0.01% | 7666 |
|
|
2016
Q3 | $9K | Buy |
77
+14
| +22% | +$1.36K | ﹤0.01% | 6862 |
|
|
2016
Q2 | $5K | Hold |
63
| – | – | ﹤0.01% | 7150 |
|
|
2016
Q1 | $5K | Sell |
63
-214
| -77% | -$13.6K | ﹤0.01% | 7024 |
|
|
2015
Q4 | $25K | Buy |
277
+14
| +5% | +$1.34K | ﹤0.01% | 6527 |
|
|
2015
Q3 | $29K | Buy |
263
+91
| +53% | +$10.5K | ﹤0.01% | 6336 |
|
|
2015
Q2 | $17K | Sell |
172
-21
| -11% | -$2.17K | ﹤0.01% | 7038 |
|
|
2015
Q1 | $21K | Buy |
193
+130
| +206% | +$13.3K | ﹤0.01% | 6954 |
|
|
2014
Q4 | $6K | Buy |
+63
| New | +$5.37K | ﹤0.01% | 8872 |
|
Other funds holding PLXP
UBS Group's PLXP Position: Q2 2023 in Review
UBS Group sold out of PLx Pharma Inc. Common Stock (PLXP) in Q2 2023, closing a stake of 51,213 shares — an estimated $6.66K sold.
UBS Group first reported a position in PLXP in Q4 2014 and held it in 34 quarters. The position peaked at $772K in Q3 2021. 4 funds tracked by Wall St. Rank hold PLXP as of Q2 2023.
- UBS Group reported no remaining PLx Pharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 51,213 PLx Pharma Inc. Common Stock shares in Q2 2023, an estimated $6.66K.
- UBS Group first reported a position in PLx Pharma Inc. Common Stock in Q4 2014 and held it in 34 quarters.
- UBS Group's PLx Pharma Inc. Common Stock position peaked at $772K in Q3 2021.
- 4 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.